The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS) Rett syndrome (RS) or Angelman syndrome (AS). Another disclosed invention is the use of cannabidiolic acid for the treatment of cognitive dysfunction. In some instances, the CBDA is provided in a substantially pure state. It may take the form of a highly purified extract of cannabis such that the CBDA is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, in some embodiments, the CBDA is synthetically produced.
